Nicolas Girard, MD, PhD, discusses data from the COCOON trial for patients with EGFR-mutant advanced non–small cell lung cancer.

Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 ...

Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion.

“Right now, only 20% of patients with EGFR-positive NSCLC survive beyond five years,” explained Joshua Bauml, vice president, ...

Janssen-Cilag International NV has announced results from the phase 3 MARIPOSA study, demonstrating a significant overall ...

Johnson & Johnson (NYSE: JNJ) has announced important overall survival (OS) results from the Phase III MARIPOSA study.

Compared to osimertinib, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended overall survival.

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung ...

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line ...

Nicolas Girard, MD, PhD, discusses the final overall survival results from the MARIPOSA trial of amivantamab plus lazertinib in EGFR-mutant advanced non–small cell lung cancer.

Despite the mass confusion between the PPP loans and ERTC tax refunds, Economic Recovery Center announced the final IRS deadline for the Employee Retention Tax Credit (ERTC) and the Families First ...

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...